Interius BioTherapeutics
Interius BioTherapeutics is a Philadelphia-based, clinical-stage biotechnology company (acquired by Kite Pharma in August 2025) developing in vivo CAR T-cell therapies that reprogram immune cells inside patients via a single IV infusion for hematologic malignancies.
- Company typePrivate
- Founded2019
- HeadquartersPhiladelphia, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Interius BioTherapeutics does
Interius BioTherapeutics was a clinical-stage biotechnology company founded in 2019 as a University of Pennsylvania spinout, developing in vivo CAR T-cell therapies for hematologic malignancies and other diseases. The company's core technology is a cell-specific gene delivery platform that reprograms immune cells directly inside the patient's body via a single intravenous infusion, eliminating the need for cell harvesting, ex vivo genetic engineering, and preconditioning chemotherapy that characterize conventional CAR-T treatments. Its lead candidate, INT2104, was the first in vivo cell therapy to enter Phase I human clinical trials for B-cell malignancies, with additional research directed at autoimmune disease indications.
The company operated as a pre-commercial, venture-backed biotech, generating no product revenue and funding its R&D through institutional equity rounds totaling nearly $100 million since inception. In August 2025, Interius was acquired by Gilead Sciences' subsidiary Kite Pharma for $350 million in cash, and its operations were integrated into Kite's cell therapy research team in Philadelphia. The acquisition provided Kite with a next-generation in vivo platform intended to complement its existing ex vivo CAR-T franchise (Yescarta and Tecartus) and potentially simplify the cell therapy treatment paradigm.
Interius BioTherapeutics firmographics
Firmographics- Name
- Interius BioTherapeutics
- Legal name
- Interius BioTherapeutics, Inc.
- Website
- https://interiusbio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Interius BioTherapeutics is a Philadelphia-based, clinical-stage biotechnology company (acquired by Kite Pharma in August 2025) developing in vivo CAR T-cell therapies that reprogram immune cells inside patients via a single IV infusion for hematologic malignancies.
- Ownership category
- akta.pro rank
Interius BioTherapeutics industry classification
Industry- Product category
- Cell Therapy / Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Interius BioTherapeutics is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Interius BioTherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Venture Funding / R&D Stage: Prior to acquisition, Interius operated as a pre-commercial biotech company developing novel gene delivery technology, funded entirely through venture capital and institutional investments. The company raised nearly $100 million since inception in 2019 through Series A and subsequent financing rounds.
Go-to-market motion1 record
Interius BioTherapeutics product offering
Product offeringCore offering
Interius BioTherapeutics develops an in vivo CAR T-cell therapy platform that reprograms patients' immune cells directly inside the body through a single intravenous infusion, eliminating the need for cell harvesting, ex vivo genetic engineering, and preconditioning chemotherapy. The company's lead clinical candidate, INT2104, is being evaluated in Phase I trials for B-cell malignancies, with the platform also being explored for autoimmune disease applications.
Product overview
Interius BioTherapeutics is developing an in vivo CAR T-cell therapy platform that reprograms immune cells directly inside patients' bodies without complex lab manipulation. The company's lead candidate INT2104 is in Phase I clinical trials for B-cell malignancies. The platform technology enables cell-specific gene delivery and eliminates the need for preconditioning chemotherapy and complex cell processing that characterizes traditional CAR-T treatments.
Differentiator
Problem solved
Functional benefit
Products and services
- INT2104
Quantifiable outcome
- First in vivo CAR T-cell therapy to enter human clinical trials (Phase I)
- +2 more outcomes
Companies that use Interius BioTherapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Interius BioTherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Interius BioTherapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Gilead Sciences / Kite PharmaflagshipGilead's subsidiary Kite Pharma acquired Interius BioTherapeutics for $350 million to integrate its in vivo CAR T-cell therapy platform into Kite's research operations. The acquisition positions Interius's technology within Kite's global cell therapy infrastructure and established commercial network.
Scale indicators6 records
Recent moves7 records
Expansion highlights2 records
Interius BioTherapeutics competitors and assessment
Company assessmentBroad incumbents
- Bristol Myers Squibb (Breyanzi, Abecma): Approved CAR-T franchises (Breyanzi for lymphoma, Abecma for myeloma) directly competing in the same hematologic malignancy space as INT2104.
- Kite Pharma (Gilead Sciences): Parent company since August 2025 and the incumbent leader in autologous CAR-T with Yescarta and Tecartus. Directly comparable as a CAR-T developer targeting B-cell malignancies with established commercial infrastructure.
- Novartis (Kymriah): Approved autologous CAR-T (Kymriah) for B-cell malignancies — the incumbent therapeutic modality Interius aims to disrupt with its in vivo approach.
Direct peers
- Umoja Biopharma: Closest direct competitor — also developing in vivo CAR-T cell therapy platforms using redirected delivery of genetic payloads to immune cells, pursuing the same simplified modality that Interius pioneered.
Emerging players
- Caribou Biosciences: Developing allogeneic CAR-T cell therapies with CRISPR-edited immune cells — competing in the next-generation CAR-T space and pursuing off-the-shelf alternatives to autologous approaches.
- Allogene Therapeutics: Pioneer of allogeneic ("off-the-shelf") CAR-T therapies targeting similar B-cell malignancies with the same goal of simplifying access to cell therapy.
- CRISPR Therapeutics: Gene-editing-based cell therapy company developing CASGEVY (with Vertex) and allogeneic CAR-T candidates — comparable in applying novel gene engineering to immune cell therapy.
- Precision BioSciences: Developing in vivo gene editing and allogeneic CAR-T therapies using ARCUS platform — directly comparable as a developer of in vivo genome editing approaches to cell therapy.
- Fate Therapeutics: iPSC-derived off-the-shelf NK and T-cell therapies for oncology and autoimmune disease — comparable as a next-generation cell therapy developer pursuing simplified treatment paradigms.
- 2seventy bio: Developer of Abecma (with BMS) and pipeline of next-generation cell therapies for hematologic malignancies — overlapping target indications and cell therapy modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Interius BioTherapeutics social profiles
Digital presenceInterius BioTherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Interius BioTherapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Interius BioTherapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Interius BioTherapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Interius BioTherapeutics
What does Interius BioTherapeutics do?
Interius BioTherapeutics develops an in vivo CAR T-cell therapy platform that reprograms patients' immune cells directly inside the body through a single intravenous infusion, eliminating the need for cell harvesting, ex vivo genetic engineering, and preconditioning chemotherapy. The company's lead clinical candidate, INT2104, is being evaluated in Phase I trials for B-cell malignancies, with the platform also being explored for autoimmune disease applications.
Is Interius BioTherapeutics a public or private company?
Interius BioTherapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Interius BioTherapeutics founded?
Interius BioTherapeutics was founded in 2019. It employs 11 to 50 people.
Where is Interius BioTherapeutics based?
Interius BioTherapeutics is headquartered in Philadelphia, United States, in the North America region.
How does Interius BioTherapeutics make money?
One revenue line is on record: venture Funding / R&D Stage.
Who are Interius BioTherapeutics's main competitors?
Broad incumbents on record are Bristol Myers Squibb (Breyanzi, Abecma), Kite Pharma (Gilead Sciences) and Novartis (Kymriah). Umoja Biopharma is listed as a direct peer. Emerging players are Caribou Biosciences, Allogene Therapeutics, CRISPR Therapeutics, Precision BioSciences, Fate Therapeutics and 2seventy bio.
Does Interius BioTherapeutics have an API?
No public API is recorded for Interius BioTherapeutics.
What industry is Interius BioTherapeutics in?
Interius BioTherapeutics's product category is Cell Therapy / Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.